Innately Innovative: IFM Therapeutics Acquired By BMS

Today BMS announced the acquisition of IFM Therapeutics, an emerging biotech focused on modulating core innate immune pathways to treat cancer and autoimmune disease.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NYSE:BMY Source Type: news